Download PDF
Clin Colon Rectal Surg 2011; 24(4): 211-221
DOI: 10.1055/s-0031-1295693
© Thieme Medical Publishers

Medical Complications of Obesity and Optimization of the Obese Patient for Colorectal Surgery

Nell Maloney Patel1 , Manish S. Patel2
  • 1Division of General Surgery, UMDNJ–Robert Wood Johnson Medical School, New Brunswick, New Jersey
  • 2Division of General Internal Medicine, UMDNJ–Robert Wood Johnson Medical School, New Brunswick, New Jersey
Further Information

Publication History

Publication Date:
06 December 2011 (online)

Also available at
    Permissions and Reprints

ABSTRACT

Obesity is a medical epidemic with an enormous impact on disease prevalence and health care utilization. In the preoperative period, an awareness of medical issues associated with obesity is an important part of the planning for surgical procedures. The authors highlight the diagnostic and treatment options for medical conditions commonly affecting the obese patient including diabetes, hypertension, coronary artery disease, and deep venous thrombosis.

KEYWORDS

Obesity - preoperative care - diabetes - hypertension - cardiovascular disease

REFERENCES

  • 1 Centers for Disease Control .Vital signs. Available at: http://www.cdc.gov/VitalSigns/AdultObesity/index.html Accessed Noember 9, 2011
    Google Scholar
  • 2 Thorpe K E, Florence C S, Howard D H, Joski P. The impact of obesity on rising medical spending.  Health Aff. 2004;  W4 480-486
    Google Scholar
  • 3 US Department of Health and Human Services .The Surgeon General's call to action to prevent and decrease overweight and obesity 2001. Rockville, MD: Office of the Surgeon General. 2001. Available at: http://www.surgeongeneral.gov/topics/obesity/calltoaction/CalltoAction.pdf Accessed November 9, 2011
    Google Scholar
  • 4 Herrera F A, Yanagawa J, Johnson A, Limmer K, Jackson N, Savu M K. The prevalence of obesity and postoperative complications in a Veterans Affairs Medical Center general surgery population.  Am Surg. 2007;  73 (10) 1009-1012
    Google Scholar
  • 5 Mullen J T, Moorman D W, Davenport D L. The obesity paradox: body mass index and outcomes in patients undergoing nonbariatric general surgery.  Ann Surg. 2009;  250 (1) 166-172
    Google Scholar
  • 6 Merkow R P, Bilimoria K Y, McCarter M D et al.. Effect of body mass index on short-term outcomes after colectomy for cancer.  J Am Coll Surg. 2009;  208 (1) 53-61
    Google Scholar
  • 7 Dindo D, Muller M K, Weber M, Clavien P A. Obesity in general elective surgery.  Lancet. 2003;  361 (9374) 2032-2035
    Google Scholar
  • 8 Flegal K M, Carroll M D, Ogden C L, Curtin L R. Prevalence and trends in obesity among US adults, 1999-2008.  JAMA. 2010;  303 (3) 235-241
    Google Scholar
  • 9 Geiss L S, Pan L, Cadwell B, Gregg E W, Benjamin S M, Engelgau M M. Changes in incidence of diabetes in U.S. adults, 1997-2003.  Am J Prev Med. 2006;  30 (5) 371-377
    Google Scholar
  • 10 Cowie C C, Rust K F, Ford E S et al.. Full accounting of diabetes and pre-diabetes in the U.S. population in 1988-1994 and 2005–2006.  Diabetes Care. 2009;  32 (2) 287-294
    Google Scholar
  • 11 Gavin L A. Perioperative management of the diabetic patient.  Endocrinol Metab Clin North Am. 1992;  21 (2) 457-475
    Google Scholar
  • 12 Lauruschkat A H, Arnrich B, Albert A A et al.. Prevalence and risks of undiagnosed diabetes mellitus in patients undergoing coronary artery bypass grafting.  Circulation. 2005;  112 (16) 2397-2402
    Google Scholar
  • 13 U.S. Preventive Services Task Force . Screening for type 2 diabetes mellitus in adults: U.S. Preventive Services Task Force recommendation statement.  Ann Intern Med. 2008;  148 (11) 846-854
    Google Scholar
  • 14 American Diabetes Association . Standards of medical care in diabetes—2011.  Diabetes Care. 2011;  34 (Suppl 1) S11-S61
    Google Scholar
  • 15 Gerstein H C, Miller M E, Byington R P Action to Control Cardiovascular Risk in Diabetes Study Group et al.. Effects of intensive glucose lowering therapy in type 2 diabetes.  N Engl J Med. 2008;  358 (24) 2545-2559
    Google Scholar
  • 16 Sheehy A M, Gabbay R A. An overview of preoperative glucose evaluation, management and perioperative impact.  J Diabetes Sci Technol.  2009;  3 (6) 1261-1269
    Google Scholar
  • 17 Rehman H U, Mohammed K. Perioperative management of diabetic patients.  Curr Surg. 2003;  60 (6) 607-611
    Google Scholar
  • 18 Jacober S J, Sowers J R. An update on perioperative management of diabetes.  Arch Intern Med. 1999;  159 (20) 2405-2411
    Google Scholar
  • 19 Salpeter S R, Greyber E, Pasternak G A, Salpeter E E. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus.  Cochrane Database Syst Rev. 2010;  (Issue 4) CD002967. 10.1002/14651858.CD002967.pub4
    Google Scholar
  • 20 Bailey C J, Turner R C. Metformin.  N Engl J Med. 1996;  334 (9) 574-579
    Google Scholar
  • 21 Dagogo-Jack S, Alberti KGMM. Management of diabetes mellitus in surgical patients.  Diabetes Spectrum. 2002;  15 44-48
    Google Scholar
  • 22 Centers for Disease Control and Prevention (CDC) . Vital signs: prevalence, treatment, and control of hypertension—United States, 1999–2002 and 2005–2008.  MMWR Morb Mortal Wkly Rep. 2011;  60 (4) 103-108
    Google Scholar
  • 23 Kannel W B, Brand N, Skinner Jr J J, Dawber T R, McNamara P M. The relation of adiposity to blood pressure and development of hypertension. The Framingham study.  Ann Intern Med. 1967;  67 (1) 48-59
    Google Scholar
  • 24 Wilson P W, D'Agostino R B, Sullivan L, Parise H, Kannel W B. Overweight and obesity as determinants of cardiovascular risk: the Framingham experience.  Arch Intern Med. 2002;  162 (16) 1867-1872
    Google Scholar
  • 25 Huang Z, Willett W C, Manson J E et al.. Body weight, weight change, and risk for hypertension in women.  Ann Intern Med. 1998;  128 (2) 81-88
    Google Scholar
  • 26 Calhoun D A, Jones D, Textor S et al.. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research.  Hypertension. 2008;  51 (6) 1403-1419
    Google Scholar
  • 27 Chobanian A V, Bakris G L, Black H R Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute et al. Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.  Hypertension. 2003;  42 (6) 1206-1252
    Google Scholar
  • 28 Persell S D. Prevalence of resistant hypertension in the United States, 2003-2008.  Hypertension. 2011;  57 (6) 1076-1080
    Google Scholar
  • 29 Bramlage P, Pittrow D, Wittchen H U et al.. Hypertension in overweight and obese primary care patients is highly prevalent and poorly controlled.  Am J Hypertens. 2004;  17 (10) 904-910
    Google Scholar
  • 30 Hall J E. Pathophysiology of obesity hypertension.  Curr Hypertens Rep. 2000;  2 (2) 139-147
    Google Scholar
  • 31 Coatmellec-Taglioni G, Ribière C. Factors that influence the risk of hypertension in obese individuals.  Curr Opin Nephrol Hypertens. 2003;  12 (3) 305-308
    Google Scholar
  • 32 Esler M, Straznicky N, Eikelis N, Masuo K, Lambert G, Lambert E. Mechanisms of sympathetic activation in obesity-related hypertension.  Hypertension. 2006;  48 (5) 787-796
    Google Scholar
  • 33 Rahmouni K, Correia M LG, Haynes W G, Mark A L. Obesity-associated hypertension: new insights into mechanisms.  Hypertension. 2005;  45 (1) 9-14
    Google Scholar
  • 34 Haynes W G, Morgan D A, Walsh S A, Mark A L, Sivitz W I. Receptor-mediated regional sympathetic nerve activation by leptin.  J Clin Invest. 1997;  100 (2) 270-278
    Google Scholar
  • 35 Satoh N, Ogawa Y, Katsuura G et al.. Sympathetic activation of leptin via the ventromedial hypothalamus: leptin-induced increase in catecholamine secretion.  Diabetes. 1999;  48 (9) 1787-1793
    Google Scholar
  • 36 Rahmouni K. Leptin-induced sympathetic nerve activation: signaling mechanisms and cardiovascular consequences in obesity.  Curr Hypertens Rep. 2010;  6 (2) 104-209
    Google Scholar
  • 37 Landesberg G, Einav S, Christopherson R et al.. Perioperative ischemia and cardiac complications in major vascular surgery: importance of the preoperative twelve-lead electrocardiogram.  J Vasc Surg. 1997;  26 (4) 570-578
    Google Scholar
  • 38 Fleisher L A. Preoperative evaluation of the patient with hypertension.  JAMA. 2002;  287 (16) 2043-2046
    Google Scholar
  • 39 Frohlich E D. Clinical management of the obese hypertensive patient.  Cardiol Rev. 2002;  10 (3) 127-138
    Google Scholar
  • 40 Rosei E A, Salvetti M, Farsang C. European Society of Hypertension Scientific Newsletter: treatment of hypertensive urgencies and emergencies.  J Hypertens. 2006;  24 (12) 2482-2485
    Google Scholar
  • 41 Eagle K A, Berger P B, Calkins H et al.. ACC/AHA Guideline Update for Perioperative Cardiovascular Evaluation for Noncardiac Surgery—Executive Summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1996 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery).  Anesth Analg. 2002;  94 (5) 1052-1064
    Google Scholar
  • 42 Weksler N, Klein M, Szendro G et al.. The dilemma of immediate preoperative hypertension: to treat and operate, or to postpone surgery?.  J Clin Anesth. 2003;  15 (3) 179-183
    Google Scholar
  • 43 Fleisher L A, Beckman J A, Brown K A ACC/AHA TASK FORCE MEMBERS et al. ACC/AHA 2007 Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery): Developed in Collaboration With the American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, and Society for Vascular Surgery.  Circulation. 2007;  116 (17) 1971-1996
    Google Scholar
  • 44 The Trials of Hypertension Prevention Collaborative Research Group . Effects of weight loss and sodium reduction intervention on blood pressure and hypertension incidence in overweight people with high-normal blood pressure. The Trials of Hypertension Prevention, phase II.  Arch Intern Med. 1997;  157 (6) 657-667
    Google Scholar
  • 45 Mikhail N, Golub M S, Tuck M L. Obesity and hypertension.  Prog Cardiovasc Dis. 1999;  42 (1) 39-58
    Google Scholar
  • 46 Wofford M R, Smith G, Minor D S. The treatment of hypertension in obese patients.  Curr Hypertens Rep. 2008;  10 (2) 143-150
    Google Scholar
  • 47 U.S. Department of Health and Human Services .How Tobacco Smoke Causes Disease: The Biology and Behavioral Basis for Smoking-Attributable Disease: A Report of the Surgeon General. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; 2010
    Google Scholar
  • 48 Sharma A M, Pischon T, Engeli S, Scholze J. Choice of drug treatment for obesity-related hypertension: where is the evidence?.  J Hypertens. 2001;  19 (4) 667-674
    Google Scholar
  • 49 Pollare T, Lithell H, Berne C. A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension.  N Engl J Med. 1989;  321 (13) 868-873
    Google Scholar
  • 50 Reisin E, Weir M R, Falkner B, Hutchinson H G, Anzalone D A, Tuck M L. Treatment in Obese Patients With Hypertension (TROPHY) Study Group . Lisinopril versus hydrochlorothiazide in obese hypertensive patients: a multicenter placebo-controlled trial.  Hypertension. 1997;  30 (1 Pt 1) 140-145
    Google Scholar
  • 51 Gress T W, Nieto F J, Shahar E, Wofford M R, Brancati F L. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study.  N Engl J Med. 2000;  342 (13) 905-912
    Google Scholar
  • 52 Reaven G M, Clinkingbeard C, Jeppesen J et al.. Comparison of the hemodynamic and metabolic effects of low-dose hydrochlorothiazide and lisinopril treatment in obese patients with high blood pressure.  Am J Hypertens. 1995;  8 (5 Pt 1) 461-466
    Google Scholar
  • 53 Sharma A M, Pischon T, Hardt S, Kunz I, Luft F C. Hypothesis: Beta-adrenergic receptor blockers and weight gain: a systemic analysis.  Hypertension. 2001;  37 (2) 250-254
    Google Scholar
  • 54 UK Prospective Diabetes Study Group . Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39.  BMJ. 1998;  317 (7160) 713-720
    Google Scholar
  • 55 Davis B R, Oberman A, Blaufox M D The Trial of Antihypertensive Interventions and Management Research Group et al. Effect of antihypertensive therapy on weight loss.  Hypertension. 1992;  19 (4) 393-399
    Google Scholar
  • 56 MacMahon S W, Macdonald G J, Bernstein L, Andrews G, Blacket R B. Comparison of weight reduction with metoprolol in treatment of hypertension in young overweight patients.  Lancet. 1985;  1 (8440) 1233-1236
    Google Scholar
  • 57 Hansson L, Lindholm L H, Niskanen L et al.. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial.  Lancet. 1999;  353 (9153) 611-616
    Google Scholar
  • 58 Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. The Heart Outcomes Prevention Evaluation Study Investigators . Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.  N Engl J Med. 2000;  342 (3) 145-153
    Google Scholar
  • 59 Julius S, Kjeldsen S E, Weber M VALUE trial group et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomized trial.  Lancet. 2004;  363 (9426) 2022-2031
    Google Scholar
  • 60 Lindholm L H, Ibsen H, Borch-Johnsen K LIFE study group et al. Risk of new-onset diabetes in the Losartan Intervention for Endpoint Reduction in Hypertension Study.  J Hypertens. 2002;  20 (9) 1879-1886
    Google Scholar
  • 61 Rosenman D J, McDonald F S, Ebbert J O, Erwin P J, LaBella M, Montori V M. Clinical consequences of withholding versus administering renin-angiotensin-aldosterone system antagonists in the preoperative period.  J Hosp Med. 2008;  3 (4) 319-325
    Google Scholar
  • 62 Kheterpal S, Khodaparast O, Shanks A, O'Reilly M, Tremper K K. Chronic angiotensin-converting enzyme inhibitor or angiotensin receptor blocker therapy combined with diuretic therapy is associated with increased episodes of hypotension in noncardiac surgery.  J Cardiothorac Vasc Anesth. 2008;  22 (2) 180-186
    Google Scholar
  • 63 Auron M, Harte B, Kumar A, Michota F. Renin-angiotensin system antagonists in the perioperative setting: clinical consequences and recommendations for practice.  Postgrad Med J. 2011;  87 (1029) 472-481
    Google Scholar
  • 64 de Courten M, Ferrari P, Schneider M et al.. Lack of effect of long-term amlodipine on insulin sensitivity and plasma insulin in obese patients with essential hypertension.  Eur J Clin Pharmacol. 1993;  44 (5) 457-462
    Google Scholar
  • 65 Hubert H B, Feinleib M, McNamara P M, Castelli W P. Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study.  Circulation. 1983;  67 (5) 968-977
    Google Scholar
  • 66 Rexrode K M, Carey V J, Hennekens C H et al.. Abdominal adiposity and coronary heart disease in women.  JAMA. 1998;  280 (21) 1843-1848
    Google Scholar
  • 67 Yusuf S, Hawken S, Ounpuu S INTERHEART Study Investigators et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study.  Lancet. 2004;  364 (9438) 937-952
    Google Scholar
  • 68 Wanahita N, Messerli F H, Bangalore S, Gami A S, Somers V K, Steinberg J S. Atrial fibrillation and obesity—results of a meta-analysis.  Am Heart J. 2008;  155 (2) 310-315
    Google Scholar
  • 69 Poirier P, Giles T D, Bray G A American Heart Association et al. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss: an update of the 1997 American Heart Association Scientific Statement of Obesity and Heart Disease from the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism.  Circulation. 2006;  113 (6) 898-918
    Google Scholar
  • 70 Ramaswamy A, Gonzalez R, Smith C D. Extensive preoperative testing is not necessary in morbidly obese patients undergoing gastric bypass.  J Gastrointest Surg. 2004;  8 (2) 159-164, discussion 164–165
    Google Scholar
  • 71 Reilly D F, McNeely M J, Doerner D et al.. Self-reported exercise tolerance and the risk of serious perioperative complications.  Arch Intern Med. 1999;  159 (18) 2185-2192
    Google Scholar
  • 72 Lee T H, Marcantonio E R, Mangione C M et al.. Derivation and prospective validation of a simple index for prediction of cardiac risk of major noncardiac surgery.  Circulation. 1999;  100 (10) 1043-1049
    Google Scholar
  • 73 Devereaux P J, Yang H, Yusuf S POISE Study Group et al. Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): a randomised controlled trial.  Lancet. 2008;  371 (9627) 1839-1847
    Google Scholar
  • 74 Bangalore S, Wetterslev J, Pranesh S, Sawhney S, Gluud C, Messerli F H. Perioperative beta blockers in patients having non-cardiac surgery: a meta-analysis.  Lancet. 2008;  372 (9654) 1962-1976
    Google Scholar
  • 75 Dunkelgrun M, Boersma E, Schouten O Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echocardiography Study Group et al. Bisoprolol and fluvastatin for the reduction of perioperative cardiac mortality and myocardial infarction in intermediate-risk patients undergoing noncardiovascular surgery: a randomized controlled trial (DECREASE-IV).  Ann Surg. 2009;  249 (6) 921-926
    Google Scholar
  • 76 McFalls E O, Ward H B, Moritz T E et al.. Coronary-artery revascularization before elective major vascular surgery.  N Engl J Med. 2004;  351 (27) 2795-2804
    Google Scholar
  • 77 Fernandez Jr A Z, Demaria E J, Tichansky D S et al.. Multivariate analysis of risk factors for death following gastric bypass for treatment of morbid obesity.  Ann Surg. 2004;  239 (5) 698-702, discussion 702–703
    Google Scholar
  • 78 Scholten D J, Hoedema R M, Scholten S E. A comparison of two different prophylactic dose regimens of low molecular weight heparin in bariatric surgery.  Obes Surg. 2002;  12 (1) 19-24
    Google Scholar
  • 79 Shepherd M F, Rosborough T K, Schwartz M L. Heparin thromboprophylaxis in gastric bypass surgery.  Obes Surg. 2003;  13 (2) 249-253
    Google Scholar
  • 80 Miller M T, Rovito P F. An approach to venous thromboembolism prophylaxis in laparoscopic Roux-en-Y gastric bypass surgery.  Obes Surg. 2004;  14 (6) 731-737
    Google Scholar
  • 81 Cotter S A, Cantrell W, Fisher B, Shopnick R. Efficacy of venous thromboembolism prophylaxis in morbidly obese patients undergoing gastric bypass surgery.  Obes Surg. 2005;  15 (9) 1316-1320
    Google Scholar
  • 82 Wille-Jørgensen P, Rasmussen M S, Andersen B R, Borly L. Heparins and mechanical methods for thromboprophylaxis in colorectal surgery.  Cochrane Database Syst Rev. 2003;  (Issue 4) CD001217
    Google Scholar
  • 83 Fleming F J, Kim M J, Salloum R M, Young K C, Monson J R. How much do we need to worry about venous thromboembolism after hospital discharge? A study of colorectal surgery patients using the National Surgical Quality Improvement Program database.  Dis Colon Rectum. 2010;  53 (10) 1355-1360
    Google Scholar
  • 84 Rasmussen M S, Jørgensen L N, Wille-Jørgensen P. Prolonged thromboprophylaxis with low molecular weight heparin for abdominal or pelvic surgery.  Cochrane Database Syst Rev. 2009;  (1, Issue 1) CD0052718 DOI: 10.1002/14651858.CD0052718.pub2
    Google Scholar
  • 85 Schuster R, Hagedorn J C, Curet M J, Morton J M. Retrievable inferior vena cava filters may be safely applied in gastric bypass surgery.  Surg Endosc. 2007;  21 (12) 2277-2279
    Google Scholar

Nell Maloney PatelM.D. 

Division of General Surgery, UMDNJ–Robert Wood Johnson Medical School

One Robert Wood Johnson Place, P.O. Box 19, New Brunswick, NJ 08901

Email: malonene@umdnj.edu